（来源：千龙网） 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内，一批微生物"工人"已经开 工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产品。与2025年同期相比，在北京昌平区落户 的合成生物制造企业数量增长近七成，产业规模持续壮大，集聚效应日益凸显。 从实验室里的毫克级样品，到工业生产线上的吨级产品，园区内，微元合成生物技术（北京）有限公司 已成功实现甘露醇、阿洛酮糖、木糖醇等产品的商业化落地，聚焦人类营养、动物营养、日化原料、药 ...

走进实验室，整齐排列的一个个生物反应器，就是一座座"无声工厂"，肉眼不可见的微生物作为"新型 工人"，一呼一吸之间就能生产各类合成生物产品，堪称"生物造万物"。刘波介绍，最近，"新型工 人"的研发也在持续进行，公司菌种库内保存的微生物样本已达十余万种，随着研发的推进，这个数字 仍在不断增长。 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 本报讯（记者 刘苏雅）春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内， 一批微生物"工人"已经开工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产 ...

Group 1 - Watson Bio announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners [1] - The target scale of the fund is 1 billion yuan, with Watson Bio contributing 450 million yuan as a limited partner [1] - The fund will primarily invest in the synthetic biology manufacturing industry, including sectors such as synthetic biology, health and wellness, bio-agriculture, bio-energy, bio-materials, and technology platform enterprises [1]

Core Insights - The company has grown from 3 to over 400 employees, supported by comprehensive policies from Changping District, including 32 targeted support measures and an investment of 80 million yuan from a municipal health fund [1][2] - Changping District aims to establish itself as a leading hub for synthetic biology manufacturing, with a focus on high-quality industrial development [1][2] Group 1: Company Growth and Support - The company has completed nearly 300 million yuan in a new round of equity financing to accelerate the development of methanol-based bio-manufacturing products [1] - Changping District has established 146 synthetic biology manufacturing enterprises and 16 common technology service platforms, with over 300 million yuan in registered capital [2] - The district has received national recognition as the first national characteristic industrial cluster in synthetic biology manufacturing [2] Group 2: Innovation and Talent Development - Changping has formed a strategic industry fund of 1 billion yuan to connect various stakeholders in the "government-industry-university-research-application" ecosystem [3] - Notable achievements include the selection of a bio-synthetic product for a major technology forum and advancements in addressing critical technology challenges [3] - The company has received approval for the production of several products, including new yeast proteins and alose sugar, with multiple products accelerating through the approval process [3] Group 3: Future Plans and Objectives - The future city group aims to incubate 10 landmark projects by 2026, enhancing the innovation center's influence and optimizing the industrial ecosystem [4] - The group has facilitated over 90 project connections and aims to secure 3 billion yuan in intended credit from financial institutions [4] - Plans include establishing a pilot base for synthetic biology manufacturing to address challenges in technology transfer [4]

Core Viewpoint - The rapid growth of Weiyuan Synthesis, supported by comprehensive policies and funding from Changping District, highlights the district's commitment to becoming a hub for synthetic biology manufacturing and innovation [1][2]. Group 1: Company Development - Weiyuan Synthesis has expanded from 3 to over 400 employees, with a recent completion of nearly 300 million yuan in equity financing to accelerate the development of methanol-based bio-manufacturing products [1]. - The company has received 80 million yuan in investment from a municipal health fund, showcasing strong governmental support for its growth [1]. Group 2: Industry Ecosystem - Changping District has established 146 synthetic biology manufacturing companies and 16 common technology service platforms, with 56 new enterprises registered since 2024 and a total registered capital exceeding 300 million yuan [2]. - The district has been recognized as the first national-level characteristic industrial cluster in synthetic biology manufacturing, enhancing its brand visibility and demonstrating its role as a future industrial growth pole [1][2]. Group 3: Innovation and Technology - Significant original achievements have emerged from Changping, including the selection of a biological synthesis technology for 2-hydroxyhexanedioic acid as a major scientific achievement for the 2025 Zhongguancun Forum [3]. - Weiyuan Synthesis has received approval for the production of several products, including alulose and new yeast proteins, with multiple products accelerating through the approval process [3]. Group 4: Future Plans - Future City Group aims to enhance the innovation center's influence, attract quality teams, and promote technology transfer, with a goal of landing 10 landmark projects by 2026 [4]. - The establishment of a pilot base for synthetic biology manufacturing is planned to address challenges in technology transfer and further solidify the region's position in the industry [4].

Group 1: Core Development Strategy - Changping District is focusing on developing new productive forces and modern industrial clusters, aiming to create a world-class modern city led by science and education [1] - The district is constructing the G6 Innovation Corridor along the Jing-Zhang Expressway and the G45 Industrial Corridor along the Jing-Cheng Expressway, promoting the integration of central enterprises and various businesses [1] Group 2: Industrial Cluster Development - Changping District plans to implement a new round of leading industry action plans, focusing on "Artificial Intelligence+" and strengthening three trillion-level industrial clusters: pharmaceutical health, advanced energy, and advanced manufacturing [2] - The district aims to develop emerging industries such as beautiful health, medical devices, robotics, hydrogen energy, energy storage, and energy internet, targeting a revenue of over 10 billion yuan for the synthetic biology manufacturing industry this year [2] Group 3: Urban Quality and Infrastructure - The district is committed to enhancing urban quality and vitality through the integration of industry and city, ensuring the construction of key rail transit and main roads, and improving park road networks and municipal facilities [2] - Changping District is advancing the development of Changping New City and the urban renewal of Yong'an Ancient City, while implementing the third round of the "Huitian Action Plan" to promote 89 key projects [2] Group 4: Public Services and Community Development - The district will focus on 36 livelihood projects this year, enhancing public employment service capabilities and promoting the construction of quality housing, communities, and urban areas [3] - Changping District is advancing the construction of high-level comprehensive hospitals and optimizing services for children and the elderly through the "Changping Model" [3]

Core Viewpoint - Changping District aims to become a vibrant destination for young people, combining historical significance with modern urban life, while establishing itself as a world-class scientific city and a hub for brain-machine industry development over the next five years [1] Group 1: Technological Innovation - Changping is a key area for Beijing's international innovation center, housing 41 universities, 64 central enterprise research institutes, and 66 national key laboratories, along with 58 academicians and 58,000 research talents [2][3] - The district plans to accelerate the construction of the Future University Science Park, covering 210,000 square meters, and establish a national technology transfer center for biomedicine [3] - The "One Park, Two Ports" strategy includes the Future University Science Park and collaborative projects with Tsinghua University and Peking University to enhance innovation and industry integration [3][4] Group 2: Industrial Development - Changping has developed three trillion-yuan industrial clusters in healthcare, advanced energy, and advanced manufacturing, with over 260,000 market entities and 41 listed companies [4][5] - The district aims to establish a distinctive brain-machine industry cluster by the end of the 14th Five-Year Plan, leveraging top research institutions and achieving significant clinical milestones [5] Group 3: Urban Development - Changping has implemented over 450 urban renewal projects, focusing on preserving cultural heritage while modernizing urban spaces, with notable projects like the Qinghua South Base and Grand Canal Heritage Park [6] - The district plans to create a historical cultural district in the old city, integrating modern design with historical landmarks [6] Group 4: Social Welfare - With a resident population of 2.27 million, including a high percentage of young people, Changping is focused on creating a youth-friendly city through comprehensive employment services and living support systems [8][9] - Initiatives include the "Rain Swallow Talent Housing Plan," providing nearly 10,000 public rental housing units, and expanding educational resources with 36 new schools and 30,000 new student placements [9][10] Group 5: Ecological and Cultural Tourism - Changping is developing a "Garden City" model, with a forest coverage rate of 49.46% and plans for a greenway system to enhance ecological connectivity [11][12] - The district aims to integrate ecological and cultural resources into tourism and agriculture, promoting new business models like rural tourism and leisure agriculture [12]

Group 1 - The core point of the article is that Jinbo Bio has received approval from the China Securities Regulatory Commission (CSRC) for a targeted stock issuance, marking the first such approval for the Beijing Stock Exchange in 2024, which is expected to enhance the refinancing system for companies listed on the exchange [1][4] - Jinbo Bio plans to issue up to 7.1757 million shares, aiming to raise a total of no more than 2 billion yuan, with the funds primarily directed towards the development of an AI-driven collagen database and product development platform [2][3] - The introduction of Yangshengtang as a strategic investor is expected to help Jinbo Bio overcome development bottlenecks and stimulate the upstream and downstream enterprises in the industry chain [2] Group 2 - The Beijing Stock Exchange has established a flexible and diverse refinancing mechanism since its inception, primarily utilizing methods such as private placements and convertible bonds, with Jinbo Bio's project being a significant breakthrough in the past two years [4] - The successful implementation of Jinbo Bio's stock issuance is anticipated to enhance overall market attention towards companies on the Beijing Stock Exchange, attracting various long-term funds and improving market liquidity and investor returns [5] - This project is expected to provide replicable and referable practical experience for future refinancing efforts on the Beijing Stock Exchange, aligning with its core mission to serve innovative small and medium-sized enterprises [5]

Core Insights - The synthetic biology manufacturing industry in China is experiencing rapid growth, with a projected market size nearing 80 billion yuan in 2024 and expected to approach 100 billion yuan in 2025, reflecting a growth rate of 26.2% compared to 2024 [1] - The industry has maintained a growth rate of over 25% for the past three years, driven by policy incentives and technological breakthroughs, leading to accelerated commercialization and increased market acceptance [1] Industry Overview - The primary products in China's synthetic biology manufacturing sector are currently biopharmaceuticals, which are expected to reach a market size of 33.43 billion yuan in 2024, accounting for 42.9% of the total industry [1] - The demand for biopharmaceutical products is anticipated to rise further due to the ongoing development of new therapies, such as cell and gene therapies, which will contribute to an increase in both product quantity and market demand [1] Future Projections - The synthetic biology manufacturing industry in China is projected to exceed 100 billion yuan by 2026 and reach approximately 170.37 billion yuan by 2027 [1]

Group 1 - The event "Synthetic Biology Manufacturing Innovation and Entrepreneurship Competition" held in Changde showcased the integration of industry, capital, and urban strategy, attracting nearly 1,000 experts and representatives from academia, industry, and investment [1][2] - The competition featured 60 teams selected from 338 projects, focusing on nine cutting-edge areas including biomedicine and AI synthetic biology manufacturing, highlighting the event's broad participation and influence [2][4] - The competition served as a key hub for linking innovative resources and industrial ecosystems, with a diverse activity matrix that included parallel events aimed at promoting collaboration and resource integration [7][9] Group 2 - The competition presented various projects demonstrating the transition of synthetic biology from laboratory to industrial application, addressing challenges in traditional agriculture and healthcare [4][19] - The establishment of the Hunan Synthetic Biology Manufacturing Standardization Technical Committee during the event marked a new phase in industry development, focusing on building common rules [7] - The awards ceremony recognized outstanding projects, providing winners with access to government funding and direct connections to industry leaders, facilitating the transition from technology to market [14][16] Group 3 - The successful hosting of the competition signifies a new starting point for Changde's industrial development, transitioning from reliance on traditional resources to becoming a hub for innovation and ecological attractiveness [19][20] - The event demonstrated a comprehensive approach to empowering the industry, including standardization, application scenario openness, and capital integration, enhancing long-term competitiveness [19] - Changde aims to merge its historical and cultural strengths with cutting-edge synthetic biology, showcasing its unique capability to drive future industrial development [19][20]